Study Comparing 2 Different Formulations of Pantoprazole in Healthy Adults.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00383916|
Recruitment Status : Completed
First Posted : October 4, 2006
Last Update Posted : March 8, 2007
|Condition or disease||Intervention/treatment||Phase|
|Healthy Subjects||Drug: pantoprazole||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label, Single-Dose, Randomized, 2-Period, Crossover, Bioequivalence Study Between the Altana Formulation of Pantoprazole Delayed-Release Granules and the Wyeth Formulation of Pantoprazole Delayed-Release Granules in Healthy Subjects.|
|Study Start Date :||October 2006|
|Study Completion Date :||October 2006|
- To determine the bioequivalence of the Altana formulation of pantoprazole to the Wyeth formulation of pantoprazole delayed-release granules.
- To obtain additional safety and tolerability data concerning pantoprazole in healthy subjects and to assess the pharmacokinetics of the Altana formulation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00383916
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|